Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VolitionRX Ltd VNRX

Healthcare Medical Instruments & Supplies
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and... see more

Recent & Breaking News (NYSEAM:VNRX)

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

PR Newswire November 14, 2024

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

PR Newswire November 8, 2024

Volition Appoints Timothy I. Still as Chairman

PR Newswire November 6, 2024

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

PR Newswire October 31, 2024

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

PR Newswire October 9, 2024

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

PR Newswire October 3, 2024

Volition Appoints Dr. Ethel Rubin as an Independent Director

PR Newswire September 30, 2024

Volition Hosts KOL Roundtable on Sepsis

PR Newswire September 11, 2024

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update

PR Newswire August 14, 2024

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering

PR Newswire August 9, 2024

VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update

PR Newswire August 6, 2024

Volition appoints PharmaVentures for Capture PCR(TM) and oncology portfolio licensing

PR Newswire July 9, 2024

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting

PR Newswire June 27, 2024

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire June 14, 2024

VolitionRx Limited to Present at Jefferies Global Healthcare Conference

PR Newswire May 29, 2024

VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update

PR Newswire May 13, 2024

VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update

PR Newswire May 8, 2024

Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech

PR Newswire April 23, 2024

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

PR Newswire March 25, 2024

VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update

PR Newswire March 21, 2024